Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant776 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT02558348 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)(AL3818) | terminated | Phase 1 / Phase 2 | 12 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer(SEASCAPE) | terminated | Phase 1 / Phase 2 | 35 | Aduro Biotech, Inc.INDUSTRY | 2 | Apr 4, 2019 | clinicaltrials |
| NCT01685255 | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | terminated | Phase 2 | 83 | Incyte CorporationINDUSTRY | 6 | Mar 11, 2019 | clinicaltrials |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | terminated | Phase 1 / Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00322881 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00866723 | Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer | terminated | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT00005029 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 12, 2018 | clinicaltrials |
| NCT01773889 | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer | terminated | Phase 2 | 2 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT00408070 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 2 | 5 | UConn HealthOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT02101684 | Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.(Greko II) | terminated | Phase 2 | 10 | Grupo Español de Tumores Huérfanos e InfrecuentesOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01936974 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma(PGA) | terminated | Phase 2 | 7 | Western Regional Medical CenterOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT00574951 | AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 2 | 23 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00585052 | A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer | terminated | Phase 2 | 11 | University of IowaOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT00331422 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00602446 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | terminated | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00652899 | Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00003532 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer | terminated | Phase 2 | 7 | Burzynski Research InstituteOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00001827 | p53 Vaccine for Ovarian Cancer | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2017 | clinicaltrials |
| NCT02278783 | Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer | terminated | Phase 2 | 1 | University of UtahOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00354601 | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01991210 | A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) | terminated | Phase 2 | 95 | Genentech, Inc.INDUSTRY | 7 | Aug 21, 2017 | clinicaltrials |
| NCT00004221 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | terminated | Phase 2 | 12 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT01972516 | Tivozanib As Maintenance Therapy In GYN | terminated | Phase 2 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01681368 | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 30, 2017 | clinicaltrials |
| NCT02417753 | AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | May 15, 2017 | clinicaltrials |
| NCT00976183 | Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma | terminated | Phase 1 / Phase 2 | 18 | Gynecologic Oncology AssociatesOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00738699 | An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer(FAR-122) | terminated | Phase 2 | 415 | MorphotekINDUSTRY | 6 | Mar 30, 2017 | clinicaltrials |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma | terminated | Phase 2 | 12 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 27, 2017 | clinicaltrials |
| NCT01659554 | A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers(HIPEC) | terminated | Phase 2 | 4 | Columbia UniversityOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01137071 | Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer | terminated | Phase 2 | 29 | Recepta BiopharmaINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT01521143 | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment(CANVAS) | terminated | Phase 2 | 91 | Prima BioMed LtdINDUSTRY | 2 | Dec 14, 2016 | clinicaltrials |
| NCT00862836 | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(ZACFAST) | terminated | Phase 1 / Phase 2 | 15 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT02469116 | Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma | terminated | Phase 2 | 18 | Washington University School of MedicineOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT01003938 | Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer | terminated | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT00003852 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | terminated | Phase 2 | 45 | UNICANCEROTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00526799 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 30 | Daniela Matei, MDOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT00522301 | Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | terminated | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00718523 | Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer | terminated | Phase 2 | 170 | Translational Research in OncologyOTHER | 8 | Jan 12, 2016 | clinicaltrials |
| NCT00313612 | Oxaliplatin and Topotecan in Advance Ovarian Cancer | terminated | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Nov 27, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT00758732 | Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma | terminated | Phase 2 | 34 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01296035 | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer(PanGem) | terminated | Phase 2 | 8 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Oct 14, 2019source: clinicaltrials